1. "An orchestra without a conductor": A qualitative exploration of the journey from symptom onset to diagnosis in patients with severe gastrointestinal dysmotility. (December 2018) Authors: Twist, K.; Ablett, J.; Wearden, A.; Paine, P.; Vasant, D.; Lal, S.; Peters, S. Journal: Clinical nutrition ESPEN Issue: Volume 28(2018) Page Start: 247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 107P Outcomes of patients with metastatic non-small cell lung cancer (mNSCLC) receiving first-line (1L) immunotherapy (IO) with or without chemotherapy (CT): Real-world (RW) evidence vs clinical trial results - CORRELATE. (December 2022) Authors: Peters, S.; Salomonsen, R.J-B.; Tattersfield, R.; Wang, A.; Xiao, Y.; Cai, L.; Sadow, S.; Jassim, R.; Liu, S.V. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 11P Association of VISTA-expressing CD66b-positive neutrophils, with response and survival benefit from pembrolizumab in advanced malignant pleural mesothelioma. (December 2022) Authors: Homicsko, K.; Zygoura, P.; Tissot, S.; Norkin, M.; Popat, S.; Curioni-Fontecedro, A.; O'Brien, M.E.R.; Pope, T.; Shah, R.; Kammler, R.; Finn, S.P.; Coukos, G.; Dafni, U.; Peters, S.; Stahel, R.A. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 125P A phase IIa study of the novel immunogenic cell death (ICD) inducer PT-112 plus avelumab ("PAVE") in advanced non-small cell lung cancer (NSCLC) patients (pts). (December 2022) Authors: Imbimbo, M.; Ghisoni, E.; Mulvey, A.; Bouchaab, H.; Mederos Alfonso, N.; Karp, D.; Camidge, D.R.; Mansfield, A.S.; Yim, C.Y.; Ames, T.D.; Price, M.; Baeck, J.; O'Donnell, J.F.; Peters, S. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 143TiPSPECTALUNG: SCREENING PATIENTS WITH THORACIC TUMORS FOR EFFICIENT CLINICAL TRIAL ACCESS. (16th March 2015) Authors: Besse, B.; Menis, J.; Adam, J.; Dziadziuszko, R.; Hasan, B.; Lacroix, L.; Peters, S.; Lacombe, D.A.; O'Brien, M.; Stahel, R.A. Journal: Annals of oncology Issue: Volume 26(2015)Supplement 1 Page Start: i44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). (September 2015) Authors: Besse, B.; Johnson, M.; Janne, P.A.; Garassino, M.; Eberhardt, W.E.E.; Besse, B.; Johnson, M.; Janne, P.A.; Garassino, M.; Eberhardt, W.E.E.; Peters, S.; Toh, C.K.; Kurata, T.; Li, Z.; Kowanetz, M.; Mocci, S.; Sandler, A.; Rizvi, N.A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S717 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 237P Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: A joint analysis of OnCovid and ESMO-CoCARE registries. (December 2022) Authors: Cortellini, A.; Dettorre, G.; Dafni, U.; Aguilar Company, J.; Castelo-Branco, L.; Lambertini, M.; Gennatas, S.; Rogado, J.; Vinal Lozano, D.; Harrington, K.J.; Tsourti, Z.; Michielin, O.A.; Pommeret, F.; Brunet Vidal, J.M.; Tabernero, J.; Pentheroudakis, G.; Gennari, A.; Peters, S.; Romano, E.; P... Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 3001 Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project. (September 2015) Authors: Kerr, K.; Dafni, U.; Schulze, K.; Thunnissen, E.; Bubendorf, L.; Hager, H.; Gately, K.; Biernat, W.; Vliegen, L.; Hernandez Losa, J.; Marchetti, A.; Cheney, R.; Warth, A.; Speel, E.J.; Blackhall, F.; Molina, M.A.; Shames, D.S.; Peters, S.; Stahel, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S595 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. (September 2015) Authors: Stahel, R.A.; Dafni, U.; Gautschi, O.; Felip, E.; Curioni-Fontecedro, A.; Peters, S.; Massutí, B.; Cardenal, F.; Aix, S.P.; Früh, M.; Pless, M.; Popat, S.; Kotsakis, A.; Cuffe, S.; Bidoli, P.; Favaretto, A.; Carcereny, E.; Sanchez Ronco, M.; Molina, M.A.; Rosell, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S711 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 57O Randomized double-blind phase II trial (PERLA) of dostarlimab (dostar) + chemotherapy (CT) vs pembrolizumab (pembro) + CT in metastatic non-squamous NSCLC: Primary results. (December 2022) Authors: Peters, S.; Lim, S.M.; Ortega Granados, A.L.O.; Pinto, G.D.J.; Fuentes, C.S.; Lo Russo, G.; Schenker, M.; Ahn, J.S.; Reck, M.; Szijgyarto, Z.; Huseinovic, N.; Zografos, E.; O'Donnell, S.; de Marinis, F. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗